Biopharma exit activity in the first half of 2026 saw a significant increase, with eighteen industry initial public offerings taking place, including two that set records as the largest public debuts in biotech history, according to a July 15 report.
This figure more than doubles last year’s total of eight IPOs. BioSpace’s historical data shows that this number marks a rebound from recent years: there were nineteen industry IPOs in 2024, thirteen in 2023, and seventeen in 2022. However, it remains well below the nearly one hundred industry IPOs recorded during the pandemic-driven investment surge of 2021.
The financial values associated with these debuts have also drawn attention within the sector. In April, obesity-focused Kailera debuted with $625 million, surpassing Moderna’s previous record from 2018. This record was soon overtaken on June 10 when Parabilis Medicines went public with $670 million.
U.S.-based biotechs entering the market have generally performed well since their listings. Veradermics, specializing in hair loss treatments, completed a $256 million IPO and has seen its stock price rise nearly 550% from its expected opening price to $118 as of July 13. Even considering its actual opening price of $37.75 per share, Veradermics leads all recent biotech IPOs by share price performance since debuting. Seven out of thirteen U.S.-listed biotechs this year have increased their value post-IPO amid overall sector strength over the past month.
Truist analysts said on July 6 that, “June was a strong month for biotech with the XBI rising 18% MoM,” attributing gains to fundamental improvements across the sector such as robust mergers and acquisitions activity and clinical readouts: “We attribute the rally to continued fundamental improvement across the sector, including robust M&A activity, a healthy IPO/follow-on financing backdrop, clinical readouts, and improving sentiment as the FDA returns to a more optically predictable review process.”
The second half of this year is already showing momentum with Scribe Therapeutics—co-founded by Jennifer Doudna—and Kalohexis filing plans for public offerings. If these proposals proceed as planned, analysts say that biotech could see its strongest IPO year since pandemic-era highs.
